8.68 USD
+0.51 (+6.24%)
8.68 USD
0 (0%)
KPTI gets a fundamental rating of 1 out of 10. The analysis compared the fundamentals against 530 industry peers in the Biotechnology industry. Both the profitability and financial health of KPTI have multiple concerns. KPTI is quite expensive at the moment. It does show a decent growth rate.
1. Profitability
1.1 Basic Checks
KPTI had negative earnings in the past year.
In the past year KPTI has reported a negative cash flow from operations.
In the past 5 years KPTI always reported negative net income.
In the past 5 years KPTI always reported negative operating cash flow.
1.2 Ratios
With a Return On Assets value of -129.50%, KPTI is not doing good in the industry: 80.94% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -129.5% | ||
| ROE | N/A | ||
| ROIC | N/A |
ROA(3y)-50.71%
ROA(5y)-51.1%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
The Gross Margin of KPTI (95.93%) is better than 96.04% of its industry peers.
In the last couple of years the Gross Margin of KPTI has remained more or less at the same level.
The Profit Margin and Operating Margin are not available for KPTI so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 95.93% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.86%
GM growth 5Y0.37%
2. Health
2.1 Basic Checks
KPTI does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, KPTI has more shares outstanding
KPTI has more shares outstanding than it did 5 years ago.
The debt/assets ratio for KPTI is higher compared to a year ago.
2.2 Solvency
KPTI has an Altman-Z score of -25.94. This is a bad value and indicates that KPTI is not financially healthy and even has some risk of bankruptcy.
KPTI's Altman-Z score of -25.94 is on the low side compared to the rest of the industry. KPTI is outperformed by 85.28% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | N/A | ||
| Altman-Z | -25.94 |
ROIC/WACCN/A
WACC8.4%
2.3 Liquidity
KPTI has a Current Ratio of 1.03. This is a normal value and indicates that KPTI is financially healthy and should not expect problems in meeting its short term obligations.
Looking at the Current ratio, with a value of 1.03, KPTI is doing worse than 86.23% of the companies in the same industry.
A Quick Ratio of 0.98 indicates that KPTI may have some problems paying its short term obligations.
KPTI's Quick ratio of 0.98 is on the low side compared to the rest of the industry. KPTI is outperformed by 85.66% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.03 | ||
| Quick Ratio | 0.98 |
3. Growth
3.1 Past
The earnings per share for KPTI have decreased strongly by -22.45% in the last year.
The Revenue has decreased by -3.98% in the past year.
The Revenue has been growing by 28.85% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)-22.45%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%2.05%
Revenue 1Y (TTM)-3.98%
Revenue growth 3Y-11.54%
Revenue growth 5Y28.85%
Sales Q2Q%13.57%
3.2 Future
KPTI is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 15.23% yearly.
KPTI is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 21.11% yearly.
EPS Next Y-25.06%
EPS Next 2Y15.11%
EPS Next 3Y17.42%
EPS Next 5Y15.23%
Revenue Next Year-1.16%
Revenue Next 2Y-1.28%
Revenue Next 3Y17.78%
Revenue Next 5Y21.11%
3.3 Evolution
Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
4. Valuation
4.1 Price/Earnings Ratio
KPTI reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for KPTI. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
KPTI's earnings are expected to grow with 17.42% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y15.11%
EPS Next 3Y17.42%
5. Dividend
5.1 Amount
No dividends for KPTI!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
8.68
+0.51 (+6.24%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners32.89%
Inst Owner Change0%
Ins Owners2.32%
Ins Owner Change1.43%
Market Cap147.99M
Revenue(TTM)142.53M
Net Income(TTM)-124.62M
Analysts83.33
Price Target14.89 (71.54%)
Short Float %1.89%
Short Ratio1.86
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-11.48%
Min EPS beat(2)-19.63%
Max EPS beat(2)-3.34%
EPS beat(4)2
Avg EPS beat(4)5.52%
Min EPS beat(4)-19.63%
Max EPS beat(4)35.04%
EPS beat(8)5
Avg EPS beat(8)20.8%
EPS beat(12)7
Avg EPS beat(12)14.92%
EPS beat(16)11
Avg EPS beat(16)25.63%
Revenue beat(2)2
Avg Revenue beat(2)2.73%
Min Revenue beat(2)0.68%
Max Revenue beat(2)4.78%
Revenue beat(4)2
Avg Revenue beat(4)-6.29%
Min Revenue beat(4)-16.5%
Max Revenue beat(4)4.78%
Revenue beat(8)4
Avg Revenue beat(8)-2.62%
Revenue beat(12)6
Avg Revenue beat(12)-2.21%
Revenue beat(16)10
Avg Revenue beat(16)14.45%
PT rev (1m)5.54%
PT rev (3m)-17.05%
EPS NQ rev (1m)-1.88%
EPS NQ rev (3m)-0.66%
EPS NY rev (1m)-1.37%
EPS NY rev (3m)-12.42%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-10.67%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0.41%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 1.04 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | N/A | ||
| P/tB | N/A | ||
| EV/EBITDA | N/A |
EPS(TTM)-14.51
EYN/A
EPS(NY)-6.78
Fwd EYN/A
FCF(TTM)-5.24
FCFYN/A
OCF(TTM)-5.24
OCFYN/A
SpS8.36
BVpS-15.79
TBVpS-15.79
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -129.5% | ||
| ROE | N/A | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 95.93% | ||
| FCFM | N/A |
ROA(3y)-50.71%
ROA(5y)-51.1%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.86%
GM growth 5Y0.37%
F-Score3
Asset Turnover1.48
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 14.8% | ||
| Cap/Sales | 0.04% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 1.03 | ||
| Quick Ratio | 0.98 | ||
| Altman-Z | -25.94 |
F-Score3
WACC8.4%
ROIC/WACCN/A
Cap/Depr(3y)20.37%
Cap/Depr(5y)20.63%
Cap/Sales(3y)0.06%
Cap/Sales(5y)0.08%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-22.45%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%2.05%
EPS Next Y-25.06%
EPS Next 2Y15.11%
EPS Next 3Y17.42%
EPS Next 5Y15.23%
Revenue 1Y (TTM)-3.98%
Revenue growth 3Y-11.54%
Revenue growth 5Y28.85%
Sales Q2Q%13.57%
Revenue Next Year-1.16%
Revenue Next 2Y-1.28%
Revenue Next 3Y17.78%
Revenue Next 5Y21.11%
EBIT growth 1Y17.33%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-12.18%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y11.57%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y11.52%
OCF growth 3YN/A
OCF growth 5YN/A
KARYOPHARM THERAPEUTICS INC / KPTI FAQ
Can you provide the ChartMill fundamental rating for KARYOPHARM THERAPEUTICS INC?
ChartMill assigns a fundamental rating of 1 / 10 to KPTI.
What is the valuation status for KPTI stock?
ChartMill assigns a valuation rating of 0 / 10 to KARYOPHARM THERAPEUTICS INC (KPTI). This can be considered as Overvalued.
How profitable is KARYOPHARM THERAPEUTICS INC (KPTI) stock?
KARYOPHARM THERAPEUTICS INC (KPTI) has a profitability rating of 1 / 10.
What is the expected EPS growth for KARYOPHARM THERAPEUTICS INC (KPTI) stock?
The Earnings per Share (EPS) of KARYOPHARM THERAPEUTICS INC (KPTI) is expected to decline by -25.06% in the next year.